Brief: Island Pharmaceuticals Says FDA Grants Co Type C Meeting Under Galidesivir's Open IND Application
19/09/2025 02:12
Sept 19 (Reuters) - Island Pharmaceuticals Ltd ILA.AX: FDA GRANTS ISLAND A TYPE C MEETING UNDER GALIDESIVIR'S OPEN IND APPLICATION WRITTEN RESPONSES FROM FDA EXPECTED BY 12 NOV (US TIME) TO REQUEST GUIDANCE ON PROPOSED CLINICAL STUDY DESIGN, GALIDESIVIR'S ELIGIBILITY FOR PRIORITY REVIEW VOUCHER Further company coverage: ILA.AX ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Island Pharmaceuticals
See all newsBrief: Island Pharmaceuticals Says Pivotal Marburg Data Secured For Galidesivir FDA Pathway
Brief: Island Pharmaceuticals Posts Prelim FY Loss Attributable Of A$9.8 Million
Australia's Island Pharmaceuticals rises as company boosts Galidesivir production
Brief: Island Pharmaceuticals Boosts Galidesivir Supply As Ebola Surges
Island Pharmaceuticals hits seven-month high on Galidesivir approval for Ebola epidemic